Apnimed is based on a simple idea – that Obstructive Sleep Apnea, or OSA, patients need a safe, effective and well-tolerated oral medication.
Cambridge, Mass
Joined August 2020
- Tweets364
- Following298
- Followers600
- Likes54
Pinned Tweet
Today we announced positive topline results from LunAIRo, our second pivotal Phase 3 trial of our investigational compound, AD109, a potential first-in-class oral pill for adults with OSA.
Two Pivotal Trials. One Bold Vision for OSA Treatment. Read more: bit.ly/412VfuS
Two Pivotal Trials. One Bold Vision for OSA Treatment. Read the story of our LunAIRo Phase 3 topline data in @FierceBiotech: fiercebiotech.com/biotech/ap…
ALT Fierce Biotech - Apnimed's Sleep Apnea Asset Goes 2 for 2 in Phase 3, Solidifying Star Potential
With two pivotal trials complete, we're closer than ever to offering millions of people living with OSA a potential first-in-class oral pill. Read about our latest Phase 3 data in the @nytimes: nytimes.com/2025/07/23/well/…
ALT The New York Times - A Pill for Sleep Apnea Could Be on the Horizon
While preparing sleep-related teaching materials as a research assistant, Miranda realized that she had been experiencing OSA symptoms for much of her life. Read her OSA story and how this diagnosis has ignited a personal passion for neuroscience: bit.ly/4egVXKA
😴 OSA isn’t just about bad sleep—it’s a serious health risk.
When left untreated, it can lead to long-term, potentially life-threatening complications. Hear what Dr. Nate Watson says your next step should be if you’re having trouble sleeping. bit.ly/3SUOAP5
You'd expect to struggle to catch your breath summiting Mt. Everest—not every night while you sleep. OSA reduces blood oxygen levels that can cause blood pressure spikes and heart rate fluctuations. Learn more about the burden of decreased oxygen in OSA: bit.ly/4400Ti8
Men and women experience OSA differently, and we’ve got the data to prove it. At 10AM, join Monica Mallampalli in Exhibit Hall 4E as she dives into the gender-specific psychosocial burden of OSA, backed by insights from our SHINE survey, at #SLEEP2025. bit.ly/4jKJG1Y
While treatment options exist for OSA, many people living with it struggle to tolerate the standard treatment.
📣 Today at 10 AM during #SLEEP2025, join us in Exhibit Hall 4E as Dr. Nate Watson spotlights the critical gaps in diagnosis and treatment of OSA:bit.ly/4mTW8PC
Revealing data presented at #SLEEP2025 estimates >80 million Americans have OSA and many are unaware, which can lead to serious health consequences. Join us at 10AM in Exhibit Hall 4E as we shine a light on this burden—and hear how we’re changing the story:bit.ly/4jJ05Uy
Right on the heels of announcing our first Phase 3 topline results, we’re gearing up to highlight the disease burden and unmet medical needs in OSA at #SLEEP2025. Make sure our presentations are part of your conference plan: bit.ly/4kR6A8M
ALT Apnimed announces multiple presentations at SLEEP 2025
Failure to effectively treat OSA can have a lasting impact on overall health and quality of life. Up to 80% of people living with OSA are undiagnosed.
Learn how we’re working to simplify solutions for people with OSA: bit.ly/4k81i8Y
Join us at #ATS2025 to explore the demographics and baseline disease characteristics of our Phase 3 LunAIRo study, evaluating investigational AD109 in people with OSA. The study includes a diverse group of people with mild, moderate, or severe OSA: bit.ly/43l0hTQ
Today marks a major milestone for our company and the OSA community—our landmark Phase 3 SynAIRgy trial met its primary endpoint. Learn more: apnimed.com/article/ad109pha…
We’re on a mission to transform the treatment of OSA. Stop by our booth at #ATS2025 for a quick chat, a fresh perspective on OSA, and a peek into what’s ahead for sleep medicine. Let’s talk science, innovation—and better sleep for millions.
ALT Apnimed's booth at ATS2025. The logo appears over a blue background with text that reads "The Dawn of a New Era in OSA. AD109 is an investigational oral tablet targeting the neuromuscular root cause of OSA."
ALT Visitors stand and look around the Apnimed booth at ATS 2025
"Sleep apnea can actually affect anyone of any age, of any sex and body type. There really isn't any single face of the disease."
@ParadeMagazine talked to Miranda Chappel-Farley about the close call that ultimately led to her OSA diagnosis. bit.ly/3F3baS5
We can’t wait to see you at #ATS2025! Stop by our booth to learn more about our efforts to develop an oral therapy to treat obstructive sleep apnea and make sure our presentation on the patient demographics of our Phase 3 LunAIRo trial is on your calendar. bit.ly/44qS82y
ALT A photo of the Golden Gate Bridge indicates ATS 2025 is in San Francisco May 16-21. Apnimed will discuss AD109 in Obstructive Sleep Apnea in a session on May 20 at 11:30 a.m. local time. AD109 is an investigational product.
OSA can have a profound impact on everyday life. The SHINE survey, sharing the psychological burden experienced by those with OSA, unpacks these often-overlooked aspects of OSA. Learn more: bit.ly/4jXXnei
#MentalHealthAwarenessMonth
A study of more than 12,000 adults found that nearly half of people with OSA are not obese. While obesity is a primary risk factor for this sleep-related breathing disease, many other factors often play a role. Read more in @NewsMedical: bit.ly/4jxlT6z
Last week, our team celebrated #SleepApneaEducationWeek, joining forces with @OfApnea and @project_sleep to break stereotypes and spread information about OSA. Let’s face sleep apnea together and make it a national priority year-round!
